Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
Status:
Recruiting
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of patients who receive
concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2
negative adenocarcinoma at gastroesophageal junction.